aTyr Pharma shareholders approve stock plan increase and report Phase 3 trial enrollment progress

aTYR PHARMA INC

Shareholders approved amendment to 2015 Stock Plan, increasing shares reserved by 3,000,000 to 10,713,670.
Svetlana Lucas and Sanjay Shukla elected as Class III directors with majority votes.
Ratification of Ernst & Young as independent auditor for FY2024 (54.5M for, 327K against).
Advisory approval of executive compensation (42.5M for, 398K against).
Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis anticipates completing enrollment in Q2 2024; final patient dosing may occur in July 2024.

item 5.02 item 5.07 item 5.05 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.